Colorectal cancer news, Folic Acid Fortification Might Boost Cancer Risk

Low-Dose Aspirin Might Lower Odds for Digestive Cancers In Colorectal cancer news, foods are not supplemented with folic acid, making it the ideal place to investigate colorectal cancer news or not the supplement increases the risk for cancer, Ebbing noted.

The report is published in the Nov.

For the study, Ebbing's team collected data on 6, patients with heart disease from two trials. These trials were designed to see if vitamin B could lower homocysteine, a protein associated with an increased risk of heart disease. In the studies, patients were randomly assigned to receive folic acid plus vitamins B12 and B6, folic acid plus B12, or B6 alone, or a placebo.

These trials ran from toand were followed through the end of The researchers found that patients who received folic acid had a 21 percent increased risk for developing cancer. In addition, of the patients who received folic acid and developed cancer, died -- a 38 percent increased risk compared with patients who did not take folic acid and developed cancer.

The most common cancers associated with folic acid were colorectal, lung, prostate and blood cancer, the researchers noted. In all, Bettina F.

Drake, an assistant professor of surgery at the Alvin J. Louis and co-author of an accompanying journal editorial, said that "while the results by Ebbing and colleagues provide some short-term data that is important in helping us understand the colorectal cancer news in the association between folic acid and cancer risk, this report does not nullify the vast potential long-term benefits that folic acid fortification may have on population health.

The true effect of folic acid on cancer may take many years of follow-up to determine, Drake said.

Cancer prevention efforts do not start or end with folic acid, Drake added. Sometimes study results do, too.

National Library of Medicine. Drake, Ph. Louis; Nov.

Ki is a marker of cell proliferation associated with a low survival in colorectal cancer patients. Its expression is increased in patients with Dukes C or D colorectal cancer versus those in stage A or B. The purpose of the study is to evaluate the immunohistochemical expression of the Ki marker in colorectal adenocarcinomas.